

13<sup>TH</sup> ANNUAL

# STATE OF THE HEART



## THREE VIRTUAL SESSIONS

May 25, June 1, 8, 2022

8:00-9:40 p.m. EST

### PLANNING COMMITTEE



**Jacques Genest,**  
MD, CM, FRCPC, FACC, FAHA  
**CO-CHAIR**  
Professor of Medicine,  
McGill University  
McGill/Novartis Chair in Medicine,  
McGill University Health Centre/  
Royal Victoria Hospital,  
Montreal, QC



**Milan Gupta,**  
MD, FRCPC, FCCS, FACC, FAHA  
**CO-CHAIR**  
Associate Clinical Professor  
McMaster University  
Medical Director, Canadian  
Collaborative Research Network  
Brampton, ON



**Ajay Kapur,**  
MD, FRCPC  
St Josephs Health Centre Toronto  
GIM at St Josephs Health Centre  
Toronto, ON



**Laura Reardon,**  
MD, CCFP, ABOM Diplomate  
Medical Director, Lotus Health Clinic  
Diplomate, American Board of  
Obesity Medicine  
Halifax, NS



**Kevin Saunders,**  
MD CCFP  
Medical Director,  
The Wellness Institute,  
Seven Oaks General Hospital  
University of Manitoba  
Winnipeg, MB



**Sol Stern,**  
B.Sc., M.Sc., MD, MCFP  
Lead, Family Physician, Argus Medical  
Centre Family Health Organization  
Co-Medical Director, Sea Courses/  
CME Away  
Ajax, ON

**Accreditation: This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 4.5 Mainpro+ credits.**

Register free online at:  
**www.ccrnmd.com**  
or use this QR code:



### AGENDA

#### SESSION 1 : Wednesday, May 25, 2022 – 8:00 - 9:40 pm EST

##### LEARNING OBJECTIVES

- Explore current role of GLP-1 agonists in clinical practice
- Recognize the impact of kidney protection for cardiac protection
- Determine when to use medical vs surgical treatment in stable CAD
- Describe appropriate antiplatelet therapy for stable CAD patients

##### Opening Comments

GLP-1 agonists: underused and underappreciated?

CKD: save the kidneys, save the heart

Stable CAD: when to use antianginals and when to revascularize

Stable CAD: ASA alone, prolonged DAPT or low-dose rivaroxaban?

##### Discussion and Q+A

Program Close

This **Group Learning** program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.50 Mainpro+ credits.

Darren McGuire  
David Cherney  
Tara Sedlak  
Marc Sabatine  
All Faculty

#### SESSION 2 : Wednesday, June 1, 2022 – 8:00 - 9:40 pm EST

##### LEARNING OBJECTIVES

- Describe a guideline centric approach to manage and support patients with obesity
- Distinguish the appropriate use of ezetimibe or PCSK9 inhibitors in secondary prevention
- Discuss the role of a new market entrance in lipid management
- Apply guideline centric strategies for managing cardiovascular risk beyond LDL-C

##### Opening Comments

Have we entered a new era in obesity management?

When to use ezetimibe or PCSK9 inhibitors in secondary prevention

Inclisiran: the new LDL kid on the block

Cardiovascular risk reduction: more than just LDL-C

##### Discussion and Q+A

Program Close

This **Group Learning** program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.50 Mainpro+ credits.

Megha Poddar  
Jacques Genest  
Milan Gupta  
Deepak Bhatt  
All Faculty

#### SESSION 3 : Wednesday, June 8, 2022 – 8:00 - 9:40 pm EST

##### LEARNING OBJECTIVES

- Summarize the benefits and challenges with using DOAC's
- Describe appropriate management strategies and therapies for managing patients with HFrEF and HFpEF
- Explore developments in cardiovascular medicine that may change how we treat patients in the future

##### Opening Comments

Lessons learned after a decade of experience with DOAC's

HFrEF: how to start and titrate the four pillars of treatment

HFpEF: which drugs have become standard of care?

CV medicine in the next decade: predicting the future

##### Discussion and Q+A

Program Close

This **Group Learning** program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.50 Mainpro+ credits.

Paul Dorian  
Nadia Giannetti  
Milan Gupta  
Deepak Bhatt  
All Faculty

This program received unrestricted educational funding from Gold: HLS Therapeutics; Silver: AstraZeneca, Bayer, BMS/Pfizer Alliance, Boehringer Ingelheim, Janssen, KYE Pharmaceuticals, Sanofi and in-kind support from Pfizer.



For inquiries regarding this program,  
please contact [info@ccrnmd.com](mailto:info@ccrnmd.com)